The first 11 coronavirus patients who arrived in Omaha last week, airlifted across the globe after two weeks quarantined on a cruise ship, showed only minor symptoms or none at all. And then one of them or one of the couple of Americans who arrived later got worse. He developed pneumonia, a life-threatening complication for coronavirus patients.<\/p>\n
In a biocontainment room at the University of Nebraska Medical Center on Friday, doctors infused him with an experimental Gilead drug once developed for Ebola, called remdesivir. Or they gave him a placebo. For the first time in the US, neither he nor the doctors knew.<\/p>\n
The first US novel coronavirus trial was underway and with it, a mad dash for an answer. Sponsored by the NIH, the study marked a critical point in the epidemic. Since the start of the outbreak, the agency had helped lead a global effort to contain the virus. Now, as it spread worldwide and the CDC issued warnings the US could see a major internal outbreak, they were looking at home.<\/p>\n
We dont have too much time, Andre Kalil, the trials lead investigator, told Endpoints News. Everythings moving really fast.<\/p>\n
Unlock this story instantly and join 73,400+ biopharma pros reading Endpoints daily and it's free. <\/p>\n
SUBSCRIBE SIGN IN <\/p>\n
<\/p>\n
Link: The first 11 coronavirus patients who arrived in Omaha last week, airlifted across the globe after two weeks quarantined on a cruise ship, showed only minor symptoms or none at all. And then one of them or one of the couple of Americans who arrived later got worse. Continue reading
\nUPDATED: Biogen makes another bold Alzheimer's bet, dropping $350M upfront to partner with genome-editing focused Sangamo - Endpoints News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"